Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)

NCT04350216 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis
Atherosclerosis

Interventions

DRUG: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]

Sponsor

Instituto de Investigación Marqués de Valdecilla